MYC regulates the antitumor immune response through CD47 and PD-L1 SC Casey, L Tong, Y Li, R Do, S Walz, KN Fitzgerald, AM Gouw, V Baylot, ... Science 352 (6282), 227-231, 2016 | 1293 | 2016 |
Reversible tumorigenesis by MYC in hematopoietic lineages DW Felsher, JM Bishop Molecular cell 4 (2), 199-207, 1999 | 1130 | 1999 |
c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma AP Weng, JM Millholland, Y Yashiro-Ohtani, ML Arcangeli, A Lau, C Wai, ... Genes & development 20 (15), 2096-2109, 2006 | 1101 | 2006 |
MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer CM Shachaf, AM Kopelman, C Arvanitis, Å Karlsson, S Beer, S Mandl, ... Nature 431 (7012), 1112-1117, 2004 | 1034 | 2004 |
MYC as a regulator of ribosome biogenesis and protein synthesis J Van Riggelen, A Yetil, DW Felsher Nature Reviews Cancer 10 (4), 301-309, 2010 | 1009 | 2010 |
MYC activation is a hallmark of cancer initiation and maintenance M Gabay, Y Li, DW Felsher Cold Spring Harbor perspectives in medicine 4 (6), a014241, 2014 | 917 | 2014 |
Sustained loss of a neoplastic phenotype by brief inactivation of MYC M Jain, C Arvanitis, K Chu, W Dewey, E Leonhardt, M Trinh, CD Sundberg, ... Science 297 (5578), 102-104, 2002 | 867 | 2002 |
NAFLD causes selective CD4+ T lymphocyte loss and promotes hepatocarcinogenesis C Ma, AH Kesarwala, T Eggert, J Medina-Echeverz, DE Kleiner, P Jin, ... Nature 531 (7593), 253-257, 2016 | 686 | 2016 |
Supramolecular stacking of doxorubicin on carbon nanotubes for in vivo cancer therapy Z Liu, AC Fan, K Rakhra, S Sherlock, A Goodwin, X Chen, Q Yang, ... Angewandte Chemie International Edition 48 (41), 7668-7672, 2009 | 638 | 2009 |
HIF-dependent antitumorigenic effect of antioxidants in vivo P Gao, H Zhang, R Dinavahi, F Li, Y Xiang, V Raman, ZM Bhujwalla, ... Cancer cell 12 (3), 230-238, 2007 | 621 | 2007 |
Transient excess of MYC activity can elicit genomic instability and tumorigenesis DW Felsher, JM Bishop Proceedings of the National Academy of Sciences 96 (7), 3940-3944, 1999 | 545 | 1999 |
Cancer revoked: oncogenes as therapeutic targets DW Felsher Nature Reviews Cancer 3 (5), 375-379, 2003 | 539 | 2003 |
Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation CH Wu, J Van Riggelen, A Yetil, AC Fan, P Bachireddy, DW Felsher Proceedings of the National Academy of Sciences 104 (32), 13028-13033, 2007 | 492 | 2007 |
The MYC oncogene — the grand orchestrator of cancer growth and immune evasion R Dhanasekaran, A Deutzmann, WD Mahauad-Fernandez, AS Hansen, ... Nature reviews Clinical oncology 19 (1), 23-36, 2022 | 486 | 2022 |
Targeted inhibition of tumor-specific glutaminase diminishes cell-autonomous tumorigenesis Y Xiang, ZE Stine, J Xia, Y Lu, RS O’Connor, BJ Altman, AL Hsieh, ... The Journal of clinical investigation 125 (6), 2293-2306, 2015 | 477 | 2015 |
Bioorthogonal cyclization-mediated in situ self-assembly of small-molecule probes for imaging caspase activity in vivo D Ye, AJ Shuhendler, L Cui, L Tong, SS Tee, G Tikhomirov, DW Felsher, ... Nature chemistry 6 (6), 519-526, 2014 | 426 | 2014 |
Cancer prevention and therapy through the modulation of the tumor microenvironment SC Casey, A Amedei, K Aquilano, AS Azmi, F Benencia, D Bhakta, ... Seminars in cancer biology 35, S199-S223, 2015 | 391 | 2015 |
CD4+ T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation K Rakhra, P Bachireddy, T Zabuawala, R Zeiser, L Xu, A Kopelman, ... Cancer cell 18 (5), 485-498, 2010 | 385 | 2010 |
Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge ahead WH Goodson III, L Lowe, DO Carpenter, M Gilbertson, A Manaf Ali, ... Carcinogenesis 36 (Suppl_1), S254-S296, 2015 | 359 | 2015 |
c-Myc is a critical target for c/EBPα in granulopoiesis LM Johansen, A Iwama, TA Lodie, K Sasaki, DW Felsher, TR Golub, ... Molecular and cellular biology 21 (11), 3789-3806, 2001 | 348 | 2001 |